Searchers can follow up by document-to-document 'walking' via chemistry-in-common, chemotype similarity, target-centric reports, authors/inventors and affiliations/assignees. However, like any database, SF has its shortcomings, some of which can be largely offset by public resources. The most significant of these for ADEV users are thin indexing of bioactivity and mmoa, including the absence of curated relationship between assay results and compound structures which are not numbered to allow facile cross-referencing to SAR tables in papers or patents.